Rates of major bleeding were numerically lower with apixaban versus enoxaparin/warfarin across body weight categories
- Major bleeding was significantly reduced with apixaban versus enoxaparin/warfarin in the >60 to <100 kg category
- RR was not estimable in the ≥100 to <120 kg category due to no major bleeding episodes reported in the apixaban arm
| Body weight category | Apixaban n/N |
Enoxaparin/Warfarin n/N |
RR (95% CI) | P interaction |
|
|---|---|---|---|---|---|
| ≤60 kg | 1/230 | 7/243 |
|
0.15 (0.02-1.15) | NE |
| >60 kg to <100 kg | 13/1920 | 32/1924 |
|
0.41 (0.21-0.77) | |
| ≥100 kg to <120 kg | 0/377 | 7/372 |
|
NE | |
| ≥120 kg | 1/144 | 3/146 | 0.34 (0.04-3.22) |
Favors apixaban
Favors enoxaparin/warfarin
